Summary
Sitaram Siddharth, who is serving as Interim Principal Financial Officer and Principal Accounting Officer at Doximity, Inc. (NASDAQ:DOCS), reported a sale of company stock and simultaneous option exercises on April 10, 2026. The sale and option exercise occurred against a backdrop of depressed share prices and a stream of analyst commentary that presents a variety of views on the companys outlook.
Insider transaction details
According to the filing, Siddharth sold 2,427 shares of Class A Common Stock on April 10, 2026, at $21.09 per share, for a total transaction value of $51,185. On that same day he also exercised stock options to purchase 5,000 shares of Class A Common Stock at an exercise price of $0.
The disposal took place while DOCS shares were trading near their 52-week low of $20.55 and roughly 67% below their level six months prior.
Market and research context
An InvestingPro analysis noted in the filing that DOCS appears undervalued at current levels and that the InvestingPro platform offers 11 additional ProTips and detailed financial health metrics for deeper review. The mention underlines that third-party research tools present a valuation case that differs from recent market pricing.
Recent analyst activity
Several brokerage firms have updated their views on Doximity in close succession. Evercore ISI lowered its rating from "Outperform" to "In Line," citing slower market growth and heightened competitive risk, and set a revised price target of $25. Freedom Capital Markets began coverage with a "Buy" rating and a $31 price target, framing that valuation around projected enterprise value-to-revenue and EBITDA metrics.
Piper Sandler, after assessing Doximitys AI tools, maintained an "Overweight" stance and raised its price target to $42. Mizuho adjusted its target down to $34 from $45, pointing to delays in pharmaceutical marketing budgets but expressing expectations for acceleration later in the year.
Takeaway
The insider sale and concurrent option exercise are factual events recorded with specific quantities and prices; they arrive amid materially lower market pricing for DOCS and a set of analyst views that span downgrades, new coverage and higher targets. The range of external opinions highlights differing assessments of growth timing, competitive dynamics and valuation.
Key points
- Siddharth sold 2,427 Class A shares on April 10, 2026, at $21.09, totaling $51,185, and exercised 5,000 options at $0.
- DOCS shares are trading near a 52-week low of $20.55 and are down 67% over the past six months.
- Analyst coverage is mixed: Evercore ISI downgraded to "In Line" (PT $25); Freedom Capital Markets initiated at "Buy" (PT $31); Piper Sandler raised its PT to $42 and kept "Overweight"; Mizuho lowered its PT to $34 from $45.
Risks and uncertainties
- Market sentiment and share price volatility - DOCS is trading near its 52-week low, reflecting significant recent price movement that affects valuation assessments.
- Revenue and budget timing in key customer segments - Mizuho attributes part of its target adjustment to delays in pharmaceutical marketing budgets, indicating uncertainty in a major revenue driver.
- Competitive and market growth risks - Evercore ISI cited slower market growth and increasing competitive threats as reasons for its downgrade.
The material above is presented as a factual account of recent filings and analyst commentary. It does not infer causation beyond what is stated in the reported documents and research notes.